Healthcare & Life Sciences
Providers, payers and pharma are converging on the same imperative: give clinicians, scientists and operators more time for the work only they can do. AI is finally credible at the bedside, the bench and the back office, when governance is engineered in across discovery, diagnostics, revenue cycle and clinical documentation.
US health systems are scaling ambient documentation and prior authorization automation. The UK NHS is piloting AI triage and radiology AI at scale. EU pharma is operationalizing AI across discovery, regulatory and commercial under the EU AI Act and EMA guidance. Emerging markets are leveraging AI for population health and access. The frontier is moving from point tools to integrated clinical and operational platforms governed under FDA SaMD and equivalent regimes.
What is happening, by region.
Mayo Clinic, Cleveland Clinic, HCA and Kaiser Permanente are scaling ambient AI, revenue cycle agents and clinical decision support, while the FDA tightens guidance on AI/ML-enabled medical devices and SaMD.
NHS England is rolling out AI in radiology, stroke pathways and elective recovery, with MHRA and NICE shaping evidence requirements for AI-enabled care.
Roche, Novartis, Sanofi and Bayer are operationalizing AI in discovery, real-world evidence and regulatory submissions under the EU AI Act, GDPR and EHDS.
Apollo, Manipal and government health systems across India, Southeast Asia and the Gulf are using AI to extend specialist capacity, accelerate diagnostics and modernize patient journeys.
What we see working inside Healthcare & Life Sciences.
AI in drug discovery and clinical trials
Target identification, molecule generation, trial design and patient matching accelerated through generative and predictive AI.
Diagnostic imaging and radiology AI
AI triage, prioritization and second-read across radiology, pathology and ophthalmology, integrated into the reading workflow.
AI-enabled revenue cycle management
Coding, denials, prior authorization and patient billing automated through document AI and agentic workflows.
Patient journey optimization
AI-orchestrated outreach, scheduling and care navigation that reduces leakage and improves outcomes across high-risk cohorts.
FDA regulatory considerations for AI medical devices
Operating models, evaluation evidence and post-market monitoring aligned to FDA SaMD and Predetermined Change Control Plans.
Generative AI in clinical documentation
Ambient scribes integrated into the EHR with structured outputs, quality measure capture and clinician-in-the-loop review.